Kenvue Inc.

Based on the provided transcript from pages 3 to 12 of the document "2058284-2974.pdf," there is no explicit mention or indication of any current or planned new fundraising activities through debt or equity. Key points include: - The company is focused on improving operational performance and executing a strategic review. - Discussions address improving growth, reducing complexity, and optimizing spending but do not mention raising capital. - There is mention of driving efficiencies, cost savings, and improving cash flow conversion. - No direct references to issuing new debt or equity or plans for fundraising. - The Board is considering strategic alternatives but no details about capital raising are disclosed. Therefore, no current or future fundraising via debt or equity is communicated in these sections.

- The company is undertaking urgent actions to curtail discretionary spend and accelerate productivity measures. - They plan to continue supporting brands at a higher level than last year but will be more choiceful, redirecting spending towards higher ROI initiatives. - Work is underway to optimize brand investment spend for higher ROI. - Modernizing and optimizing systems, processes, and technologies is a key enabler to drive digital and data strategies, productivity, and efficiency. - The supply chain transformation is expected to deliver benefits across inventory and payables, improving cash flow conversion. - No specific dollar amounts or detailed future capital expenditure plans were disclosed, but investments are focused on modernization, innovation, and operational improvements.

- Guidance for 2025 expects low single-digit declines in organic sales for the full year, with potential to be at the top of that range if innovations and other factors are incremental (Page 12). - The first half closed at around a 2.7% decline; category softness and cautious consumer sentiment are factored into guidance (Page 12). - Innovation in the second half and lapping trade accruals and China weakness in Q4 may improve results (Page 12). - Global consumption stabilized for the first time since Q3 2023, but organic sales continue to lag (Page 6). - Some brands like Tylenol and Nicorette show strong growth and share gains, indicating pockets of growth (Pages 6, 7, and 9). - Overall, the expectation is cautious with a focus on innovation, brand execution, and reduced complexity to drive sustainable growth (Pages 9, 11, 12).

- Full-year organic sales guidance is a low single-digit decline, reflecting a soft category environment and cautious consumer sentiment (Page 12). - EPS guidance range is $1 to $1.05, including a low single-digit drag from currency (Page 7). - Adjusted operating margin is expected to contract versus last year due to strategic price investments, fixed cost deleverage, inflationary pressures, and tariffs (~$150 million gross impact), which are only partially offset by productivity initiatives (Page 7). - Urgent actions are underway to curtail discretionary spend and accelerate productivity for margin improvement (Pages 7, 12). - Despite earnings headwinds, cash flow is expected to remain in the same neighborhood as last year, driven by working capital and supply chain improvements (Page 11). - Innovation and brand investments will be more focused and choiceful to drive higher ROI and sustainable growth (Page 7). - A strategic review is ongoing, which may influence future growth and margin trajectories (Pages 10, 11).

The provided pages do not mention specific details about the current or expected order book or pending orders. The discussion primarily covers: - Sales guidance: Expecting low single-digit declines for the full year, including what was seen in the first half. - Category softness: Categories have softened with cautious consumer sentiment factored into guidance. - Inventory dynamics: Retail inventory destocking and trade accrual lapsing affecting sales, especially in China and the U.S. - Operational focus: Emphasis on innovation, execution, and category management to drive sales improvements. - No explicit data or commentary on order books or pending orders is provided in these pages.